Generated Narrative: Evidence 557352 version: 1; Last updated: 2026-04-08 13:56:39+0000 Profile: ComparativeEvidence ArtifactPublicationStatus: Active url: https://fevir.net/resources/Evidence/557352 identifier: FEvIR Object Identifier/557352, outcomeId/313959, picoId/85798, sectionId/73215 name: Nonfatal_stroke_from_MAGICapp_313959 title: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes citeAs: MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557352. Revised 2026-04-08. Available at: https://fevir.net/resources/Evidence/557352. Computable resource at: https://fevir.net/resources/Evidence/557352#json. status: Active author: Computable Publishing®: MAGIC-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com UseContexts - Code Value[x] * Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication (Evidence Communication) ComparativeEvidence copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ RelatesTos - Type Target[x] * Part Of MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report) description: This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide. assertion: SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists. variableDefinition description: Adults with type 2 diabetes variableRole: Population observed: Adults with type 2 diabetes and CVD and CKD variableDefinition description: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA variableRole: Exposure comparatorCategory: GLP-1 RA observed: GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA variableDefinition description: Nonfatal stroke variableRole: Outcome observed: Nonfatal stroke synthesisType: SYSTEMATIC_REVIEW studyDesign: NOTSET statistic description: Risk Difference 2.7% (CI95 0.4% to 5.3%) statisticType: risk difference quantity: 0.027 SampleSizes - NumberOfStudies NumberOfParticipants * 2 1282 AttributeEstimates - Type Range * CI95 0.004-0.053 statistic description: OR 1.2 (CI95 1.03 to 1.41) statisticType: odds ratio quantity: 1.2 SampleSizes - NumberOfStudies NumberOfParticipants * 2 1282 AttributeEstimates - Type Range * CI95 1.03-1.41 certainty description: Due to serious imprecision type: Overall certainty rating: Moderate certainty Subcomponents - Type Rating * Risk of Bias NOTSET * Inconsistency NOTSET * Indirectness NOTSET * Imprecision NOTSET * Publication Bias NOTSET
MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes
MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557352. Revised 2026-04-08. Available at: https://fevir.net/resources/Evidence/557352. Computable resource at: https://fevir.net/resources/Evidence/557352#json.
Computable Publishing®: MAGIC-to-FEvIR Converter
MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes
This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.
SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.
Adults with type 2 diabetes and CVD and CKD
GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA
Risk Difference 2.7% (CI95 0.4% to 5.3%)